Xegen

Executive Summary

Xegen is a French Contract Research Organization (CRO) founded in 2018, specializing in bioinformatics and biostatistics for Next-Generation Sequencing (NGS) and RNA-seq data analysis. The company offers tailored solutions for genomics, transcriptomics, metagenomics, and immunogenetics, serving both academic and biopharmaceutical clients. By providing customized analytical services and proprietary software tools, Xegen positions itself as a single point of contact for complex sequencing data interpretation. Despite being a relatively young and private company with limited disclosed funding or valuation, its niche focus on bioinformatics within the growing NGS market suggests potential for steady growth through service contracts and software licensing. The company's ability to scale will depend on client acquisition and retention in a competitive CRO landscape.

Upcoming Catalysts (preview)

• Q4 2026Launch of new proprietary bioinformatics software module for single-cell RNA-seq analysis60% success
• TBDMajor contract win with a top-20 pharmaceutical company for immunogenetics data analysis40% success
• Q2 2026Partnership with a leading sequencing platform provider to offer integrated analysis pipelines50% success